PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, PNH
Clinical trials for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, PNH explained in plain language.
Never miss a new study
Get alerted when new PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, PNH trials appear
Sign up with your email to follow new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, PNH, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug SLN12140 aims to control PNH in early trial
Disease control Not yet recruitingThis phase II trial tests the drug SLN12140 in 10 adults with PNH who have never taken complement inhibitors. The goal is to see if SLN12140 can reduce red blood cell destruction (measured by LDH levels) and improve hemoglobin. Participants receive different doses over 12 to 64 w…
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, PNH
Phase: PHASE2 • Sponsor: Linno Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Could a new pill tame a rare blood disease? early safety trial begins
Knowledge-focused Not yet recruitingThis early-stage trial is testing an experimental oral drug called TUL321 in healthy adults to see if it is safe and tolerable. The study will also measure how the drug moves through the body and whether food affects its absorption. TUL321 is being developed as a potential treatm…
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, PNH
Phase: PHASE1 • Sponsor: Zhuhai United Laboratories Co., Ltd. • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC